Differential expressions of AT-rich interacting domain-containing protein 1A gene, BAF250a protein and serum carbohydrate antigen 125 in ovarian serous tumors / 肿瘤研究与临床

ABSTRACT

Objective:To investigate the differential expressions of AT-rich interacting domain-containing protein 1A (ARID1A) gene and its encoding protein BAF250a and serum carbohydrate antigen 125 (CA125) in different ovarian serous tumor tissues.Methods:The tumor tissues of 97 patients with serous ovarian tumors who were treated by surgery and confirmed by surgical pathological results in Shanxi Provincial Cancer Hospital from August 2015 to September 2018 were collected. Among them, 11 cases were benign lesions (serous cystadenoma, serous fibroadenoma, serous surface papilloma, control group), 21 cases were borderline lesions (atypical proliferative serous tumor, AP group). There were 35 cases in low-grade serous carcinoma (LC) group and 30 cases in high-grade serous carcinoma (HC) group (including 5, 7, 9 and 9 cases in stage Ⅰ-Ⅳ). Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression of ARID1A mRNA in tumor tissues of each group, Western blot and immunohistochemistry were used to detect the expression and morphology of BAF250a protein in tumor tissues, and enzyme-linked immunosorbent assay was used to detect the concentration of serum CA125 in each group. The differences of ARID1A gene, BAF250a protein and serum CA125 expressions in each group were compared, and the correlation of their expressions in HC group with the clinical stage of patients was analyzed.Results:The relative expressions of ARID1A mRNA and BAF250a protein in the tumor tissues of the control group, AP group, LC group, and HC group decreased in sequence, and the serum CA125 concentration increased in sequence, the differences were statistically significant [1.37±0.02, 0.68±0.03, 0.42±0.04, and 0.29±0.14, F = 3.753, P = 0.008; 1.33±0.11, 0.81±0.11, 0.51±0.11, and 0.39±0.11, F = 10.753, P = 0.001; (23.72±2.26), (36.83±13.11), (412.55±41.71), and (529.96±61.44) U/ml, F = 10.440, P = 0.003]. Immunohistochemistry showed that the high expression rates of BAF250a protein in the control group, AP group, LC group, and HC group were 90.0% (10/11), 85.7% (18/21), 70.0% (21/35), and 33.3% (10/30). In HC group, the serum CA125 concentration increased with the increase of clinical stage [stage Ⅰ-Ⅳ (461.33±23.18), (483.51±41.21), (507.78±33.41), and (543.19±47.82) U/ml, r = 0.510, P = 0.015], and the relative expressions of ARID1A mRNA and BAF250a protein decreased with the increase of clinical stage (stage Ⅰ-Ⅳ 0.33±0.10, 0.28±0.11, 0.21±0.08, and 0.17±0.07, r = -0.329, P = 0.030; 3.83±0.13, 3.08±0.16, 2.61±0.18, and 2.07±0.13, r = -0.651, P = 0.002). Conclusion:The decrease of expressions of ARID1A gene and its encoding protein BAF250a, and the increase of CA125 expression in ovarian serous tumor tissues may indicate the malignant change and invasion of tumors.